Merck & Co., Inc.


Latest Trade






Today's Range




52 Week Range




As of on the New York Stock Exchange ∙ Minimum 15 minute delay


Previous Close
3M AVG Volume
Today's High
Today's Low
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Forward P/E
Dividend (Yield %)

Next Event

Dividend For MRK.N - 0.6900 USD

Latest Developments


Merck Says U.S. FDA Accepts For Priority Review The Supplemental BLA For Vaxneuvance

Merck's Keytruda Approved In Japan In Combination With Chemotherapy For Esophageal Carcinoma

Merck Says FDA Accepts Submission Of sNDA For Lynparza As Treatment Breast Cancer, Grants Priority Review


About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.


Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd



United States


Executive Leadership

Kenneth C. Frazier

Executive Chairman of the Board

Robert M. Davis

President, Chief Executive Officer, Director

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.04 mean rating - 25 analysts
Revenue (MM, USD)
















Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)

Latest News

Latest News

Belgium in talks to buy 10,000 doses of Merck's COVID-19 pill, health minister says

Belgium is in talks with U.S.-based Merck & Co Inc to buy 10,000 doses of its COVID-19 antiviral pill jointly developed with Ridgeback Biotherapeutics, the country's federal health minister said on Wednesday.

U.S. FDA panel narrowly backs Merck's at-home COVID-19 pill

A panel of expert advisers to the U.S. Food and Drug Administration on Tuesday narrowly voted to recommend the agency authorize Merck & Co's antiviral pill to treat COVID-19.

Canada to ask air arrivals to take COVID tests except on U.S. flights

Canada, seeking to halt the spread of the Omicron coronavirus variant, will require people arriving by air from all nations except the United States to take a COVID-19 test, Health Minister Jean-Yves Duclos said on Tuesday.

Canada says in talks with Pfizer, Merck over COVID-19 antiviral drugs

The Canadian government said on Tuesday it was in advanced talks with Pfizer Inc and Merck & Co Inc regarding a purchase agreement for COVID-19 antiviral drugs.

U.S. FDA advisers recommend authorization of Merck's COVID-19 pill

A panel of outside advisers to the U.S. Food and Drug Administration on Tuesday voted in favor of authorizing Merck & Co oral COVID-19 pill, saying the drug's benefits outweigh its potential risks.

Merck says its COVID-19 drug should be effective against any variant

Merck & Co Inc's experimental COVID-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on Tuesday.

U.S. FDA panel to weigh Merck's COVID-19 antiviral drug

A panel of expert advisers to the U.S. Food and Drug Administration will vote later on Tuesday on whether to recommend authorization of Merck & Co's antiviral pill to treat COVID-19.

Merck's COVID-19 pill significantly less effective in new analysis

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.

BRIEF-U.S. FDA Publishes Briefing Documents On Merck's Covid-19 Pill

* U.S. FDA PUBLISHES BRIEFING DOCUMENTS ON MERCK & CO INC'S COVID-19 PILL Source text: ( Further company coverage:

Merck says COVID-19 pill cuts hospitalization, death risk by 30%

Merck & Co Inc said on Friday its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

Vietnam says Pfizer, MSD to grant its firms licenses to produce COVID-19 pills

Drugmakers Pfizer Inc and MSD, known as Merck & Co Inc in North America, have agreed to give licenses to firms in Vietnam to produce COVID-19 treatment pills, Vietnam's ministry of health said on Friday.

EU to issue decision on Merck's COVID pill 'within weeks'

The European Union's drug regulator said on Tuesday it has started reviewing U.S. drugmaker Merck & Co Inc's experimental COVID-19 antiviral pill for adults following an application and could issue an opinion "within weeks."

Swiss reserved up to 8,640 doses of Merck's COVID-19 drug

The Swiss government said on Tuesday it had reserved up to 8,640 doses of Merck's COVID-19 drug Molnupiravir.

EU advises on Merck COVID pill as reviews rival from Pfizer

The European Union's drug regulator has issued advice on using Merck's COVID-19 pill for adults and began a review of a rival tablet from Pfizer to help member states decide on quick adoption ahead of any formal EU-wide approval.

U.S. looking to broaden access to COVID-19 antiviral pills - WSJ

The Biden administration is looking at ways to broaden access to potential COVID-19 antiviral pills when supply increases in the coming months, the Wall Street Journal reported on Friday, citing a person familiar with the plans.

EU recommends Merck COVID-19 pill for adults at risk of severe illness

The European Union's drug regulator on Friday advised that an experimental COVID-19 pill from Merck should be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of their disease worsening.

EU recommends Merck COVID-19 pill for adults at risk of severe illness

The European Union's drug regulator on Friday advised Merck and Ridgeback Biotherapeutics' experimental COVID-19 pill can be given within five days of first symptoms to treat...

U.S. to buy 10 million courses of Pfizer's COVID-19 pill for $5.3 billion

Pfizer Inc said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.

EU drug regulator aims to conclude Merck COVID-19 antiviral pill approval by the end of 2021

The European Medicine Agency's review to approve Merck's antiviral pill molnupiravir, developed with Ridgeback Therapeutics, is set to conclude by the end of the year, the regulator's head of vaccine strategy said on Thursday.

Italy to acquire 50,000 courses for each of Merck, Pfizer COVID-19 antiviral drugs

Italy's COVID-19 Special Commissioner was given a mandate by the health ministry to acquire 50,000 courses of each of Merck's and Pfizer's COVID-19 antiviral drugs, his office said in a statement.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.